BUZZ-TransCode Therapeutics rises on US government grant for cancer therapy

Reuters09-05

** Shares of drug developer TransCode Therapeutics rise 4.3% to 24 cents premarket

** Co says it has been awarded a $2 mln grant by the National Institutes of Health to support the clinical evaluation of its experimental therapy TTX-MC138

** Funds under the grant are expected to be received over two years - RNAZ

** TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer- RNAZ

** Co says it has recently activated three clinical trial sites to conduct an early-stage trial of the therapy in advanced solid tumors

** The trial is designed to evaluate of the safety of TTX-MC138

** Up to last close, stock down 96.4% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment